Eribulin Monomethanesulfonate
Breast Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 89/ 100
Competitive context
208 Active assets in the Breast Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trastuzumab SWOG Cancer Research Network | Phase 4 | BBB |
Trastuzumab Deruxtecan SWOG Cancer Research Network | Phase 4 | BBB |
Tamoxifen Dartmouth-Hitchcock Medical Center | Phase 4 | BBB |
Zoledronate Washington University School of Medicine | Phase 4 | BBB |
Pertuzumab SWOG Cancer Research Network | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Eribulin Monomethanesulfonate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →